26 Advanced Solid Tumors Clinical Trials in Scottsdale, AZ (2026)

Q: How do I join a clinical trial in Scottsdale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you.

Recruiting Advanced Solid Tumors Studies in Scottsdale

NCT06960395Recruiting

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination...

Scottsdale, AZPHASE1450 participantsVir Biotechnology, Inc.

View Study Details

NCT04657068Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can ...

Scottsdale, AZPHASE1442 participantsArtios Pharma Ltd

View Study Details

NCT05824975Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembro...

Scottsdale, AZPHASE1358 participantsGI Innovation, Inc.

View Study Details

NCT05720117Recruiting

A Study of PYX-201 in Advanced Solid Tumors

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (OR...

Scottsdale, AZPHASE1330 participantsPyxis Oncology, Inc

View Study Details

NCT05785754Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Esca...

Scottsdale, AZPHASE1320 participantsDynamiCure Biotechnology

View Study Details

NCT05753722Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors....

Scottsdale, AZPHASE1270 participantsIncendia Therapeutics

View Study Details

NCT06259552Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an...

Scottsdale, AZPHASE1232 participantsSparX Biotech(Jiangsu) Co., Ltd.

View Study Details

NCT06810544Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an op...

Scottsdale, AZPHASE1191 participantsTango Therapeutics, Inc.

View Study Details

NCT05405595Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic s...

Scottsdale, AZPHASE1186 participantsAdagene Inc

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Scottsdale, AZPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT07042100Recruiting

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multip...

Scottsdale, AZPHASE1177 participantsSun Pharma Advanced Research Company Limited

View Study Details

NCT06747585Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

Scottsdale, AZPHASE1170 participantsAlentis Therapeutics AG

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

Scottsdale, AZPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT07524348Recruiting

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors...

Scottsdale, AZPHASE1149 participantsSamsung Bioepis Co., Ltd.

View Study Details

NCT06819735Recruiting

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single age...

Scottsdale, AZPHASE1125 participantsDomain Therapeutics Australia Pty Ltd

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

Scottsdale, AZPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT06249048Recruiting

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Pati...

Scottsdale, AZPHASE1108 participantsStrand Therapeutics Inc.

View Study Details

NCT06266299Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors...

Scottsdale, AZPHASE1101 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Scottsdale, AZPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Scottsdale, AZPHASE185 participantsAlyssum Therapeutics

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Scottsdale, AZPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT04282044Recruiting

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination w...

Scottsdale, AZPHASE160 participantsBioEclipse Therapeutics

View Study Details

NCT06086522Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body...

Scottsdale, AZPHASE154 participantsQualigen Theraputics, Inc.

View Study Details

NCT06770764Recruiting

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic s...

Scottsdale, AZPHASE150 participantsTrutino Biosciences Inc.

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

Scottsdale, AZPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT06607939Recruiting

ORB-021 In Patients With Advanced Solid Tumors

The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanc...

Scottsdale, AZPHASE136 participantsOrionis Biosciences Inc

View Study Details

About Advanced Solid Tumors Clinical Trials in Scottsdale

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 26 advanced solid tumors clinical trials recruiting participants in Scottsdale, AZ. These studies are seeking a combined 4,566 participants. Research is being sponsored by Vir Biotechnology, Inc., Artios Pharma Ltd, GI Innovation, Inc. and 23 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Scottsdale — FAQ

Are there advanced solid tumors clinical trials in Scottsdale?

Yes, there are 26 advanced solid tumors clinical trials currently recruiting in Scottsdale, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Scottsdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you about next steps.

Are clinical trials in Scottsdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Scottsdale studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 26 active trials in Scottsdale are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 19, 2026 from ClinicalTrials.gov